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received immunotherapy. The reasons for not receiving immuno-
therapy included transplant related death (6%), inadequate recov-
ery for acute toxicity (16%), failure to obtain insurance coverage
(8%), progression of disease (8%), and patient’s/physician’s choice
(10%). The median time to start therapy was 70 days (range
32–100 days). There were no immunotherapy related deaths. By
NCI Common Toxicity Criteria, the following grade 3–4 toxicities
were seen: grade 4 hematological (n 4), grade 3 infection (n 3),
grade 4 circulatory (n  1), grade 4 gastrointestinal (n  1), grade
3 neurological/neuro-central (n  1), and grade 3 dermatology
(n  1). The most common toxicity was erthyema/induration at
injection sites. For all patients, the median follow-up is 50 months.
If one compares the outcome of patients who survived transplant
and did not have early relapse as to whether they received immu-
notherapy or not, the following outcomes were seen. The survival
rate is 63% versus 43% for patients with inﬂammatory disease. For
stage IV disease the median survival without immunotherpy was 20
months versus 39 months with immunotherapy. Median time to
disease progression was 18 months with immunotherpy and 12
months without immunotherapy. Immunotherapy with IL-2 and
GM-CSF is well tolerated after ASCT. Immunotherapy appears to
impact on survival but relapse still remains a problem for patients
with advanced breast cancer after ASCT.
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USE OF PEG-FILGRASTIM OR FILGRASTIM AFTER HIGH DOSE CONDI-
TIONING WITH BEAC CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA
Richart, J.M.1, Kallogjeri, D.1, Oliver, D.A.1, Petruska, P.J.1,
Pincus, S.M.1 Saint Louis University, Saint Louis, MO.
Colony stimulating factors are routinely used after high dose
chemotherapy and autologous transplant. Few data are available
addressing the efﬁcacy of PEG-ﬁlgrastim. Thirty-one consecutive
patients who underwent BEAC conditioning and autologous trans-
plant for lymphoma at a single institution were analyzed. One
patient died prior to neutrophil recovery and is not included in this
analysis. Nineteen patients received ﬁlgrastim either 480 mcg if
they weighed 	60 kg or 300 mcg for a weight 60 kg subcutane-
ously daily starting day 5 and continuing until ANC 	 500.
Eleven patients received 6 mg PEG-ﬁlgrastim on day 1. The
median number of CD34 cells/kg was 3.9 (1.7–8.2) in the ﬁl-
grastim group and 2.9 (1.7–9.1) in the PEG-ﬁlgrastim group. The
median number of prior cytotoxic chemotherapeutic regimens was
1 (1–3) in the ﬁlgrastim group and 1 (1–2) in the PEG-ﬁlgrastim
group. Diagnoses in the ﬁlgrastim group: diffuse large B-cell lym-
phoma (6), follicular lymphoma (7), or mantle cell lymphoma (6).
Diagnoses in the PEG-ﬁlgrastim group: diffuse large B-cell lym-
phoma (2), follicular lymphoma (3), mantle cell lymphoma (3),
anaplastic T cell lymphoma (1), or cutaneous T cell lymphoma (2).
For the ﬁlgrastim group, the median time to neutrophil engraft-
ment was 10 days (9–13); the median time to platelet engraftment
was 10 days (8–15). For the PEG-ﬁlgrastim group the median time
to neutrophil engraftment in was 11 days (8–16); the median time
to platelet engraftment was 14 days (10–16). The median number
of injections in the ﬁlgrastim group was 5 (4–7). Conclusions:
Both ﬁlgrastim and PEG-ﬁlgrastim allow for prompt neutrophil
recovery in patients undergoing BEAC conditioning and autolo-
gous transplant. Factors other than efﬁcacy such as convenience,
patient comfort and cost should be considered when choosing a
post transplant colony stimulating factor.
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DOES GM-CSF ALTER THE PROGNOSTIC SIGNIFICANCE OF EARLY LYM-
PHOCYTE RECOVERY POST-AUTOGRAFTING FOR NHL?
Tiwari, D.1, Vij, R.1, Devine, S.1, DiPersio, J.1, Khoury, H.J.2 1.
Washington University School of Medicine, St. Louis, MO; 2. Emory
University School of Medicine, Atlanta, GA.
Early lymphocyte recovery, assessed by an absolute lymphocyte
count (ALC,	 500/mcl) measured on post-transplant day 15, is an
independent prognostic factor for disease-free and overall survival
after autografting multiple myeloma, NHL, metastatic breast can-
cer, and AML. The effect of post-transplant administration of
myeloid growth factors on the prognostic signiﬁcance of ALC is
unknown. We analyzed the outcomes of 268 relapsed chemo-
sensitive NHL patients autografted at Washington University be-
tween January 1996 and May 2003, divided into 2 groups based on
their day 15 ALC counts (	500, n  151; 500, n  117). All
patients received GM-CSF 250 mcg/kg subcutaneously starting on
day 0 to hasten neutrophils recovery. Patient were well balanced
between the 2 groups with regards to age, gender, preparative
regimen, prior therapy, time from diagnosis to transplant, and
number of CD34 cells infused within each grade. Median fol-
low-up was 22 months. No associations between early lymphocyte
recovery and reduction of post-transplant complications, or im-
provement of disease-free and overall survival were observed. Late
lymphocyte recovery (ALC  500 on day 15) was independently
associated with a delay in platelet recovery (29 vs 21 days, P 
.0005) in patients who have not received pre-transplant rituximab.
We conclude that, in this single-center retrospective analysis, the
favorable prognostic signiﬁcance of post-transplant early lympho-
cyte recovery could not be reproduced and may have been due to
post-transplant administration of GM-CSF.
281
EBV-ASSOCIATED POST-TRANSPLANTATION LYMPHOPROLIFERATIVE
DISORDERS; A REPORT OF THREE CASES IN AUTOLOGOUS HSCT PA-
TIENTS OF T CELL LYMPHOMA
Koseki, M.1, Uryu, H.1, Takeuchi, M.1, Matsue, K.1 Kameda Medical
Center, Kamogawa, Chiba, Japan.
Epstein-Barr virus(EBV)-associated post-transplant lymphopro-
liferative disorders(PTLD) mostly occur in solid organ and allo-
geneic hematopoietic stem cell trnasplant(HSCT) patients with
immunosuppression associated with high mortality rate but follow-
ing autologous HSCT is rare complication. We report 3 cases of
PTLD after autologous HSCT for T cell lymphoma. One is
successfully treated with rituximab in durable remission but the
other 2 without rituximab therapy died in aggressive clinical
courses. T cell lymphoma could be a risk factor of developing
PTLD after autologous HSCT due to its speciﬁc T cell dysfunc-
tion. Currently, use of rituximab provides far better outcome that
biopsy conﬁrmed diagnosis should be made in those high risk
patients.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT) A SINGLE CEN-
TER 10 YEARS EXPERIENCE
Guillermo, C.1, Diaz, L.2, Isaurralde, H.1, Topolansky, L.2,
Baubeta, A.1, Lizarralde, A.1, Testa, G.1, Perdomo, S.1, Perdomo, A.1,
Lavagna, G.1, Nese, M.2 1. Centro IMPASA de Trasplante de Medula
Osea CITMO, Montevideo, Uruguay; 2. Hematological Department.
Medicine Department, University of Medicine, Montevideo, Uruguay.
We evaluated the results of SCT at CITMO between 1995 and
2005. We performed 323 SCT; 281 autologous (auto-SCT): 164
lymphomas (Lym), 49 MM, 43 AL, 23 solid tumors (ST), 2 others;
42 allogeneic (allo-SCT): 11 AL, 11 CML, 8 MDS, 6 AA, 3 Lym,
3 others. Nineteen auto-SCT and 10 allo-SCT were tandem.
Median age was 44 years (3–65), 160 male and 121 female for
auto-SCT, 39 years (6–58), 26 male and 16 female for allo SCT.
The conditioning regimens were: CVB, BEAC, BEAM in Lym;
BuCy in AL; Melfalan in MM; Maxi-ICE in ST; Cy-ATG in AA.
We used a maintenance treatment in ALL with Mtx and 6 MP.
Stem cells mobilized with G-CSF were obtained from BM in 16,
BM  PB in 127, and PB in 183. The median MNC and CD34
infused was 9  108/kg and 9  106/kg in auto-SCT and 7 
108/kg and 8  106/kg in allo-SCT. Hematological recovery me-
dian time was: 10 and 11 days for neutrophils; 14 and 18 for
platelets in auto and allo respectively. One hundred days mortality
was 2.6% in auto-SCT, 5.3% in tandem-SCT, and 31% in allo-
SCT; hospitalization median time was 20, 26, and 46 days, respec-
tively. Ten year overall survival in auto-SCT was: NHL 38%; HL
75%; AML 45%; ALL 73%; MM 36%; germinal tumor 63%, and
15% in breast cancer, in auto-SCT tandem was: MM 57%, NHL
60%, and HL 67%, in allo-SCT was: AA 33%, CML 41%; AL
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18%; MDS 17%; NHL 33%. These data show: no signiﬁcantly
difference in the patients outcome between BM or PB SC; auto
SCT has a low transplant related morbi-mortality. The higher
relapse rate in ALL and ST was in the ﬁrst year, and AML and
Lym in the ﬁrst 4 years, then the survival curve reaches a plateau,
so the remaining patients should be cured. The tandem SCT in
MM lets see a signiﬁcantly better overall survival at 10 years. Lym
that relapse after the ﬁrst auto-SCT can beneﬁt from a second
transplant with similar survival that obtained after ﬁrst auto-SCT,
although a bigger number of patient is required to conclude deﬁ-
nitely. We think higher ALL overall survival than the literature
reports, is in relationship with the maintenance treatment. We
emphasize the allo-SCT higher mortality, without relapse after
ﬁrst year except in MDS. Randomized protocols to evaluate main-
tenance treatment pos SCT and non-mieloablatives allo-SCT are
now in development.
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AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
ACUTE MYELOID LEUKEMIA IS RELATIVELY SAFE AND PROVIDES
LONG-TERM DISEASE CONTROL
Ganguly, S.1, Divine, C.L.1, Deauna-Limayo, D.1, Bodensteiner, D.C.1,
Lewis, J.L.1, Curran, K.1, Skikne, B.S.1 University of Kansas Medical
Center, Kansas City, KS.
Autologous stem cell transplantation (ASCT) in patients with
acute myeloid leukemia (AML) is often used as a consolidation
therapy after attaining morphologic and cytogenetic remission.
ASCT is often the only option when a suitable donor is not
available for patients who needed further intensiﬁcation of treat-
ment. In an attempt to examine whether ASCT provides long-term
disease control in patients with AML, we retrospectively evaluated
our experience and analyzed the outcomes of ASCT in patients
with AML from 1986 to 2005. Twenty-three males and 26 females
(n  49) of median age 44 years (range 15–68 years) were treated.
Of these, 42 were in CR at the time of transplantation, and 7
patients were transplanted with active disease. Thirty-three pa-
tients were transplanted in ﬁrst remission. Bone marrow was used
in 26 patients as the source of stem cells prior to 1995 and
peripheral blood stem cells (PBSC) were used in 20 patients. Three
patients received a combination of marrow and PBSC. Forty-eight
of 49 patients engrafted (96%). Median time for neutrophil recov-
ery was 17.5 days (range 9–69 days) and 42 days (range 16–303
days) for platelets. Patients who received PBSC achieved granulo-
cyte and platelet engraftments earlier than patients who received
bone marrow as the source of stem cells. Median duration of
follow-up was 8.5 years (range 29 days–18 years). Of the 49 pa-
tients, 32 had died. Five patients (9%) died within 100 days of
transplantation. Overall survival (OS) and disease-free survival
(DFS) of all evaluable patients were 27% and 33%, respectively.
Median duration of response was 11.4 months. No relapses oc-
curred after 2.2 years. OS and DFS in patients transplanted in CR
were 32% and 38%, respectively. For those transplanted with
disease (n  7), a complete response was achieved in 4 patients
(57%), with a median survival of 166 days. Disease status at trans-
plantation was a signiﬁcant variable for survival (P  .01). Most
frequent cause of death was disease relapse (19 out of 32 patients).
Two patients developed late onset myelodysplastic syndrome. In
conclusion, ASCT in patients with AML in whom an allogeneic
transplantation is not feasible appears to be a safe alternative and
provides long-term disease control.
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A REVIEW OF THE USE OF TOPOTECAN FOR MOBILIZATION OF PE-
RIPHERAL BLOOD STEM CELLS IN AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Pring, K.1, Hale, G.1, Barﬁeld, R.1, Horwitz, E.1, Kasow, K.1,
Leung, W.1, Woodard, P.1, Yusuf, U.1, Handgretinger, R.1 St Jude
Children’s Research Hospital, Memphis, TN.
Topotecan is an active agent in many pediatric malignancies. For
patients with high risk malignancies for whom consolidation with
autologous hematopoietic stem cell transplantation is an option,
the use of topotecan for mobilization of hematopoietic progenitor
cells is promising. However, there are limited published data on
topotecan as a mobilizing agent in pediatric patients with solid
tumors. We retrospectively reviewed the medical records of ap-
proximately 90 patients undergoing autologous hematopoietic
stem cell transplantation from December 2001 to December 2004
at our institution. We identiﬁed patients who received topotecan
with the purposes of collecting peripheral blood progenitor cells
after its administration. These patients had the following diseases:
Neuroblastoma, Ewings/PNET, and Wilms tumor. Some patients
did have evidence of bone marrow involvement prior to hemato-
poietic stem cell collection. Topotecan was administered at a dose
of 0.75–2 mg/m2/day on days 1–5. GCSF at 10 mcg/kg/day was
administered starting 1 day after the completion of chemotherapy.
Eight of the 17 patients failed to mobilize peripheral blood pro-
genitor cells. Following a nadir of the absolute neutrophil count,
peripheral blood CD34 counts were monitored once the ANC
reached 500/cm. Once the absolute peripheral blood CD34 count
met or exceeded 20, apheresis was performed. Nine patients un-
derwent apheresis and had an adequate number of peripheral blood
CD34 cells collected. The median CD34 collection was 6.495 
106 CD34/kg (range 1.806–9.895). All these patients subse-
quently went on to autologous hematopoietic stem cell transplan-
tation using a variety of conditioning regimens. All patients en-
grafted post transplant. Patients with early stage disease such as
neuroblastoma may have sufﬁcient numbers of peripheral blood
cells following topotecan mobilization. This data suggests that
topotecan is an active agent for mobilization of peripheral blood
cells in newly diagnosed or minimally treated patients.
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HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION (ASCT) IN HODGKIN’S DISEASE (HD) WITH >2 RE-
LAPSES—TATA MEMORIAL HOSPITAL DATA
Sastry, P.S.R.K.1, Narayanan, P.1, Bakshi, A.1, Bhagwat, R.1,
Biswas, G.1, Khadwal, A.1, Mishra, B.K.1, Parikh, P.M.1 Tata Memo-
rial Hospital, Mumbai, Maharashtra, India.
Background: Relapsed or refractory Hodgkin’s Disease (HD)
patients have a poor prognosis with standard salvage chemother-
apy, yielding a cure rate of 20% or less. High dose chemotherapy
followed by ASCT is an accepted salvage treatment in relapsed
Hodgkin’s Disease with improvement in Disease Free and Overall
Survival. We present our experience with ASCT in Hodgkin’s
Disease in patients who had 2 or more relapses. Patients and
Methods: A total of 19 patients have undergone ASCT for HD
over a period of 12 years. There were 15 males and 4 females.The
source of stem cells was Peripheral Blood in all the 19 cases. The
conditioning regimen used was BEAM in 13 (68%) and ICE in 6
(32%). Results: The median age was 28 years. The median num-
ber of relapses pre ASCT were 2.3 (range 2–4) and the median
time for ﬁrst relapse after initial chemotherapy was 24 months.
The median time from ﬁrst relapse to ASCT was 29 months.After
a median follow-up of 16.5 months, 63% of patients are alive
(overall survival) with no evidence of disease in 53% (disease free
survival). The Transplant Related Mortality (TRM) is 10%. Con-
clusions: ASCT is an effective salvage treatment in multiply re-
lapsed Hodgkin’s Disease with acceptable TRM and good disease
free and overall survival.
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PREVENTION OF MUCOSITIS IN AutoBMT/STEM CELL TRANSPLANT
PATIENTS
Klocke, J.1, Cannon, M.1, Devoe, C.1, Gissinger, D.1, John, V.1,
Bayer, R.-L.1 North Shore University Hospital, Manhasset, NY.
It is estimated that 80% of patients who undergo high-dose
chemotherapy / radiotherapy prior to transplantation develop
mucositis. Mucositis is a painful complication, which can lead to
poor nutrition, increased use of narcotics, dehydration, greater risk
for infection and bacteremia, and altered quality of life. Patients
can have oral ulceration, epigastric discomfort, diarrhea, rectal
irritation, and bleeding. It is likely that the complications of mu-
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